Blog

Quality improvement and human subjects research often intersect. Executive IRB Chair Sara Harnish discusses questions to differentiate the two.

Oncology drugs in phase I trials are usually conducted on patients with cancer due to their inherent risk. Advarra IRB member Ran Goldman expands:

How does investigator-initiated research differ from other types of clinical research? Advarra IRB Chairperson Robert Romanchuk explains.

Stem cell clinics with unproven treatments are on the rise in the US. Learn how the FDA is working to bring new stem cell therapies under federal oversight.

Learn best practices of survey creation to help measure process improvement among stakeholders at an organization.

Questions still remain about GDPR and its applications. Have you considered these six key questions to ask within your organization?

CBD, a non-psychoactive cannabinoid, is experiencing a massive surge in popularity, but clinical research lags behind in verifying effective uses.

On March 5, 2019, Advarra announced its acquisition of Quorum Review IRB and Kinetiq, the research and technology consulting division of Quorum.

We have cancelled our webinar “After the Compliance Date: Revised Common Rule FAQs,” which was originally scheduled for February 28.

If your research must comply with the revised Common Rule, you’ll need to update the way you write ICFs to meet the new requirements.

While many US researchers are aware of the coming Common Rule changes, not everyone is sure whether they will need to comply with the revised regulations.

Learn what the regulations say about IRB reporting requirements for serious adverse events and how undefined “gray areas” can be addressed.